Lotus Pharmaceutical announced at its institutional investor conference on the 21st that it will launch a new five-year growth plan starting next year. The company aims to achieve US$1.5 billion (approximately NT$45.2 billion) in revenue between 2026 and 2030 through four key strategies: continuous expansion of its R&D pipeline, licensing and introducing high-potential innovative products into Asia, acquiring established brand-name drugs, and pursuing strategic acquisitions of companies or platforms.
Benefiting from business integration with Teva in Thailand, along with strong sales growth in Vietnam and export markets, Lotus reported after-tax profit of NT$1.435 billion in the first quarter of this year—a quarterly increase of 26.7% and an annual increase of 38.5%. Earnings per share (EPS) reached NT$5.47, setting a new record for the same period. Consolidated revenue from January to April totaled NT$7.303 billion, representing a 16.39% year-on-year increase.
According to Bjartur Shen, Deputy CEO of Lotus, the company’s three core strategies—continued product development, licensing high-potential innovative products into Asia, and acquiring mature brand drugs—alone have the potential to generate US$1.5 billion in revenue. If additional mergers or platform acquisitions are successfully executed, the revenue forecast could be further revised upward, providing even greater momentum for growth.
Under the R&D strategy, Lotus will focus on first-to-file generics, 505(b)(2) modified formulations, and Day-1 launches of generics. These efforts are expected to contribute US$800 million in revenue between 2026 and 2030. Licensing of innovative products with high potential for the Asian market is projected to bring in nearly US$300 million, while the acquisition of established brand-name drugs for the region is expected to generate US$400 million.
Looking ahead, Lotus is currently pursuing an acquisition in Vietnam, with the signing expected to be completed between late May and early June. Additionally, the company has the opportunity to finalize the acquisition of another business before the end of the year.
Regarding shifting U.S. tariff policies, Shen noted that the current impact remains uncertain. However, Lotus has proactively completed inventory stocking of its blood cancer drug Lenalidomide in the U.S. through 2026, ensuring no impact on this year’s revenue. With domestic manufacturing in the U.S. becoming an increasing trend, Lotus is also open to commissioning its affiliate Alvogen’s production facilities in the U.S.
As for President Trump’s proposed “Most Favored Nation” drug pricing policy, Shen stated that although branded drugs account for 90% of the market's value, they represent only about 10% of total market volume, and thus the potential negative impact on Lotus would be very limited.
Resource: 美時五年成長計畫 拚創15億美元營收
